Oklo stock tumbles as Financial Times scrutinizes valuation
McKesson Corporation’s stock has reached an all-time high, trading at $776.22. According to InvestingPro data, analysts see further upside potential, with price targets ranging from $680 to $900. This milestone underscores a significant year for the pharmaceutical distribution company, which has seen its stock price increase by 50.85% over the past year, supported by management’s aggressive share buyback program. The surge in McKesson’s stock price reflects strong market confidence and robust performance, positioning the company favorably amidst the competitive healthcare sector. With a market capitalization of $96.3 billion and an "GREAT" financial health score from InvestingPro, the achievement of this all-time high highlights McKesson’s strategic initiatives and operational efficiencies, which have resonated well with investors and contributed to its impressive growth trajectory. Discover 16 additional exclusive insights and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, McKesson has seen a flurry of activity from analysts revising their price targets and assessments. TD Cowen has increased its price target for McKesson to $864, maintaining a Buy rating, following the company’s Investor Day where it raised its long-term adjusted earnings per share guidance and set higher targets for its North America Pharmaceutical and Oncology/multispecialty adjusted operating income. UBS also raised its price target to $860, highlighting McKesson’s strong cash flow conversion and strategic reinvestments in growth markets. Mizuho adjusted its price target to $770, maintaining a Neutral rating, as McKesson addressed investor concerns by raising its long-term EPS growth guidance. Leerink Partners increased their target to $850, citing robust growth dynamics in McKesson’s pharmaceutical segments. In contrast, Jefferies lowered its price target to $84, maintaining a Buy rating, due to tariff and geopolitical pressures, although McKesson’s management has upheld its fiscal year guidance. These developments reflect varied analyst perspectives on McKesson’s growth and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.